Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lexaria Bioscience (LEXX) Asset Writedowns and Impairment (2016 - 2025)

Lexaria Bioscience's Asset Writedowns and Impairment history spans 8 years, with the latest figure at $213824.0 for Q3 2025.

  • For Q3 2025, Asset Writedowns and Impairment rose 527.0% year-over-year to $213824.0; the TTM value through Aug 2025 reached $163748.0, up 427.0%, while the annual FY2025 figure was $247364.0, 3087.68% up from the prior year.
  • Asset Writedowns and Impairment for Q3 2025 was $213824.0 at Lexaria Bioscience, up from -$50076.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $213824.0 in Q3 2025 and bottomed at -$50076.0 in Q3 2024.
  • The 3-year median for Asset Writedowns and Impairment is $19250.0 (2021), against an average of $50562.0.
  • The largest annual shift saw Asset Writedowns and Impairment surged 180.55% in 2021 before it skyrocketed 527.0% in 2025.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $13500.0 in 2021, then tumbled by 470.93% to -$50076.0 in 2024, then surged by 527.0% to $213824.0 in 2025.
  • Per Business Quant, the three most recent readings for LEXX's Asset Writedowns and Impairment are $213824.0 (Q3 2025), -$50076.0 (Q3 2024), and $13500.0 (Q3 2021).